WuXi AppTec Sues to Block Pentagon Designation That Could Trigger BIOSECURE Act Restrictions
WuXi's complaint targets the evidence behind the Pentagon’s listing of the contractor as a ‘Chinese military company’ as well as the statutory thresholds for making such determinations at all.
Medtech Insight - June 16, 2026

Self-Care Steps Into The Spotlight
Guest Article: Luis Rhodes Baiao, AESGP's governmental and public affairs director, shares his key takeaways from the association's recent Annual Meeting in Berlin.
HBW Insight - June 16, 2026

As Roche Joins The BTK Degrader Race, BeOne Stays Just Ahead
Roche has bought into Nurix’s strong BTK degrader competitor, bexobrutideg, but BeOne will be first with a pivotal readout for its candidate, tacabrutideg, in this burgeoning drug class.
Scrip - June 16, 2026

Alvotech Secures Fresh Cash As FDA Milestones Mount
Alvotech’s $152m financing boosts near-term liquidity after a sharp Q1 cash decline, while funding a biosimilar pipeline that management says is approaching a key US launch inflection point.
Generics Bulletin - June 16, 2026

enGene Retrenches On Detalimogene As Bladder Cancer Race Tightens
After a disappointing update on detalimogene voraplasmid in May, EnGene will cut down its workforce by half and let several executives go to focus attention on a H2 2026 FDA filing.
Scrip - June 16, 2026

Neumora Pivots To Broader Pipeline After Navacaprant Fails In MDD
While the trial failures will see Neumora cut costs and focus on its wider pipeline, the data raise further questions over the efficacy of kappa opioid receptor antagonists in major depressive disorder.
Scrip - June 16, 2026

Stock Watch: Launching Brands Into A Biosimilar Market
Launching a product that proves less commercially successful than its best-performing peers in an indication is no bad thing as long as the late-comers are also blockbusters. But will they fare so well once biosimilars to the forerunners appear?
Scrip - June 16, 2026

Egg-Based Biologics Platform Wins $23m Investor Backing
Neion Bio has raised an oversubscribed $23m Series A to advance its Raptor platform, which uses genetically engineered chicken eggs to produce complex biologics, including biosimilars.
Generics Bulletin - June 16, 2026

CinnaGen Converts Teriparatide Setback Into European Regulatory Breakthrough
CinnaGen’s first EU approval gives the Iranian biosimilars player a regulated-market foothold, turning an earlier teriparatide setback into a launch platform for Zandoriah across Europe’s increasingly competitive Forsteo biosimilar field.
Generics Bulletin - June 16, 2026

Harmonized EU Supplement Limits Are Coming: What To Do Before The Clock Runs Out
EU harmonized maximum limits for vitamins and minerals in supplements are finally moving towards reality. With no formal impact assessment planned, the upcoming consultation is industry's best opportunity to shape the outcome - but preparation must start now, according to HBW's expert panel.
HBW Insight - June 16, 2026

Obesity Research Is Surging Even As Overall Trial Volumes Decline
Obesity became the second most studied disease in 2025 with 184 trials – more than double the field's previous peak – as GLP-1 dominance reshapes a research landscape that has collapsed twice before on safety concerns.
In Vivo - June 16, 2026

Mabworks, RemeGen Snag World-First Approvals For Renal Disorder, Sjögren’s Drugs In China
Mabworks' obinutuzumab and RemeGen's telitacicept help expand China’s growing list of global first-in-class drugs approved in the country before anywhere else, in this case for primary membranous nephropathy, and Sjögren’s disease/immunoglobulin A nephropathy, respectively.
Scrip - June 16, 2026

No Single Partner: How Leading Hospital Systems Are Building Multi-Vendor AI Ecosystems
Across prominent health systems, a structural pattern is emerging: Projects like the Cleveland Clinic’s five-vendor pilot and Mayo’s proprietary frontier model indicate a trend toward multi-vendor strategies.
Medtech Insight - June 16, 2026

FDA’s Animal-Testing Alternatives Guidance Leaves Validation Bar Unsettled, Industry Says
Whether CDER draft guidance reaches CBER-regulated biologics is also among questions industry groups and sponsors have as they press US FDA to spell out validation and qualification expectations and show how new approach methodologies fit within a weight-of-evidence framework.
HBW Insight - June 16, 2026